Search Results for "message"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for message. Results 11 to 20 of 140 total matches.
In Brief: Propylthiouracil for Hyperthyroidism
The Medical Letter on Drugs and Therapeutics • Jul 27, 2009 (Issue 1317)
Licenses, Reprints
or call customer service at: 800-211-2769
Important Copyright Message
IN THIS ISSUE ...
The thionamides propylthiouracil and methimazole are both used to treat hyperthyroidism.1 Propylthiouracil causes severe hepatic toxicity or hepatic failure in about 0.1% of adults and children.2,3 It is the third leading cause of liver transplants due to drug toxicity (acetaminophen and isoniazid are the first two). Methimazole may cause less serious hepatic toxicity; reversible cholestatic jaundice has been reported. There is generally no good reason to continue to use propylthiouracil, with 2 possible exceptions. First, propylthiouracil may be preferred for treatment of life-threatening...
Addendum: Why Not Ertapenem for Surgical Prophylaxis?
The Medical Letter on Drugs and Therapeutics • Sep 07, 2009 (Issue 1320)
Important Copyright Message
IN THIS ISSUE (starts on next page)
Addendum: Why Not Ertapenem for Surgical ...
Some readers have asked why the June 2009 issue of Treatment Guidelines (Antimicrobial Prophylaxis for Surgery) did not recommend use of ertapenem (Invanz) for prevention of infection after elective colorectal surgery. Ertapenem is a broad-spectrum carbapenem that has been approved for such use by the FDA. Medical Letter consultants do not recommend use of broad-spectrum drugs such as ertapenem, third-generation cephalosporins such as cefotaxime (Claforan), ceftriaxone (Rocephin), cefoperazone (Cefobid), ceftazidime (Fortaz, and others) or ceftizoxime (Cefizox), or fourth-generation...
Addendum: Cost of Ustekinumab (Stelara)
The Medical Letter on Drugs and Therapeutics • Mar 08, 2010 (Issue 1333)
Important Copyright Message
IN THIS ISSUE (starts on next page)
Addendum: Ustekinumab ...
In the Medical Letter article on ustekinumab (Stelara) for psoriasis (2010; 52:7), footnote 2 in table 2 should have included a second sentence: $5595.60 is the cost of one 45-mg syringe.
In Brief: A New Hib Booster
The Medical Letter on Drugs and Therapeutics • Nov 02, 2009 (Issue 1324)
Important Copyright Message
IN THIS ISSUE (starts on next page)
In Brief: A New Hib Booster ...
In 2007, Merck voluntarily recalled some lots of PedvaxHIB and Comvax, two Haemophilus influenzae type b (Hib) vaccines, and temporarily stopped their production because of possible contamination, resulting in a shortage during which pediatricians were urged to defer giving Hib booster doses (normally given at 12-15 months) to healthy children. Now the FDA has granted accelerated licensure of Hiberix (GlaxoSmithKline), a monovalent vaccine conjugated with tetanus toxoid that has been used in Europe since 1996, as a booster (final) dose of the Hib series in children 15 months-4 years old....
Correction: Ferumoxytol (Feraheme)
The Medical Letter on Drugs and Therapeutics • Apr 19, 2010 (Issue 1336)
Important Copyright Message
IN THIS ISSUE (starts on next page)
Correction: Ferumoxytol (Feraheme ...
In the Medical Letter article on Ferumoxytol (Feraheme) - A New Parenteral Iron Formulation (2010; 52:23), the last sentence of the Dosage, Administration and Cost paragraph should have listed the cost of 1 gram of sodium ferric gluconate (Ferrlecit) as about $600.
A Stool DNA Test (Cologuard) for Colorectal Cancer Screening
The Medical Letter on Drugs and Therapeutics • Oct 13, 2014 (Issue 1453)
or call customer service at: 800-211-2769
Important Copyright Message
The Medical Letter®
on Drugs ...
The FDA has approved Cologuard (Exact Sciences),
a stool DNA test, to screen average-risk adults ≥50
years old for colorectal cancer.
In Brief: Different Diets
The Medical Letter on Drugs and Therapeutics • Mar 23, 2009 (Issue 1308)
Important Copyright Message
IN THIS ISSUE (starts on next page)
In Brief: Different Diets ...
A recent article in the New England Journal of Medicine confirms something that others, including The Medical Letter (Treat Guidel Med Lett 2008; 6:23), have been saying for years: no particular combination of protein, carbohydrate and fat in the diet offers any advantage in losing weight. This randomized 2-year trial followed 800 overweight and obese subjects on low fat/average protein, low fat/high protein, high fat/average protein, and high fat/high protein diets. Carbohydrate intake varied from 35% (in the high fat/high protein diet) to 65% (in the low fat/average protein diet). All...
In Brief: Plan B for 17-Year Olds
The Medical Letter on Drugs and Therapeutics • May 18, 2009 (Issue 1312)
Important Copyright Message
IN THIS ISSUE (starts on next page)
In Brief: Plan B for 17-Year Olds ...
The FDA has announced that it will lower the age for over-the-counter access to the emergency contraceptive Plan B1 from 18 to 17 years old. In a randomized, controlled trial, the two 0.75-mg levonorgestrel tablets in Plan B, taken 12 hours apart beginning within 72 hours after unprotected intercourse, decreased the overall pregnancy rate to 1.1% (11/976) of women who requested emergency contraception.2 The sooner the drug is taken after coitus, the more effective it is. Nausea and vomiting can occur with Plan B. Fetal malformations have not been associated with pregnancies that occurred...
In Brief: Injectable Paliperidone Palmitate for Schizophrenia
The Medical Letter on Drugs and Therapeutics • Nov 02, 2009 (Issue 1324)
Important Copyright Message
IN THIS ISSUE (starts on next page)
In Brief: Injectable Paliperidone ...
Paliperidone palmitate (Invega Sustenna – Ortho-McNeil Janssen) has been approved by the FDA as a once-monthly injection for acute and maintenance treatment of schizophrenia in adults. An extended-release oral formulation (Invega) has been available since 2006.1 Long-acting injections of antipsychotic drugs typically are used to treat patients who cannot adhere to an oral regimen.2,3 Paliperidone is the primary active metabolite of risperidone (Risperdal), which is also available as a long-acting (every 2 weeks) injection. It is unclear whether either risperidone or paliperidone is a better...
In Brief: Cardiac Risks of Antipsychotic Drugs
The Medical Letter on Drugs and Therapeutics • Feb 23, 2009 (Issue 1306)
Important Copyright Message
IN THIS ISSUE (starts on next page)
In Brief: Cardiac Risks of Antipsychotic ...
A recently published retrospective cohort study in patients 30-74 years old has led to headlines in the media warning that use of atypical antipsychotic drugs doubles patients’ risk of sudden cardiac death. Typical antipsychotics have long been associated with this risk. In this study, however, the incidence of sudden cardiac death was similar with typical and atypical antipsychotics: about 1 in 340 person-years among the patients who took typical (first generation) antipsychotics such as haloperidol (Haldol, and others) and 1 in 360 personyears among those who took atypical...